---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069338"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:57:53.533774+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M

## Summary
- EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.
- Executed global licensing agreements for Vitargus (up to $187M) and oncology products (up to $105M) totaling potential $292M.
- Received $116,000 cash milestone in June 2024 from Vitargus licensing.
- Shareholders' equity stood at $7.8M as of June 30, 2024.
- Obtained US, Taiwanese, and Australian patents for Polygala extract for MDD and ADHD; FDA approved four INDs for oncology.

## SEC filing metadata
- accession: 0001213900-24-069338
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/0001213900-24-069338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/ea0211475-8k_abvc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069338
- JSON: https://secwatch.observer/filing/0001213900-24-069338.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.